The Importance of Subgroup Analysis in Drug-Eluting Stent Trials

JACC Cardiovasc Interv. 2016 Jan 11;9(1):39-41. doi: 10.1016/j.jcin.2015.11.006.
No abstract available

Keywords: chronic kidney disease; drug-eluting stent(s); women.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Coronary Artery Disease / drug therapy
  • Coronary Restenosis / drug therapy*
  • Drug-Eluting Stents*
  • Humans
  • Myocardial Infarction / drug therapy
  • Paclitaxel
  • Sirolimus / therapeutic use
  • Stents
  • Time Factors
  • Treatment Outcome

Substances

  • Paclitaxel
  • Sirolimus